drugset / Trial / NCT00560781

Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs

NCT00560781

Completed 27 enrolled Durham VA Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test the therapeutic potential of augmenting a stable SSRI regimen with the neurosteroid pregnenolone to reduce cognitive symptoms and PTSD symptoms in patients diagnosed with PTSD.

Timeline

Start
2006-04
Primary completion
2007-04
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregnenolone Other / unclassified 50 mg
Comparator Pregnenolone Other / unclassified 150 mg
Comparator Pregnenolone Other / unclassified 250 mg